deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02072070

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis

Sponsor: Kolon Life Science

Conditions Degenerative Arthritis
Interventions Placebo TissueGene-C
Updated 7 times since 2017 Last updated: Nov 14, 2017 Started: Nov 30, 2013 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Degenerative Arthritis and is currently completed. Kolon Life Science leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshotCompleted~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Dec 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Dec 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kolon Life Science
Data source: Kolon Life Science

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations